Is it an opportunistic time to buy HIMS?

**The opportunistic time to buy HIMS might not be currently.** Here's why:

1. **Financial Performance**: Hims & Hers Health (HIMS) has shown strong revenue growth with a 51.82% increase to $315.65 million by Q2 2024. However, the net income has significantly declined with a 285.79% growth rate to $13.3 million, and the diluted EPS has decreased by 56.45%. This indicates a concerning trend in profitability.

2. **Market Sentiment**: The stock's P/E ratio is negative at -2131.09, which typically suggests that investors expect further losses in the future. However, the P/S ratio is 4.22, indicating that the market is willing to pay a premium for the company's sales. The RSI is 65.35, which is close to the overbought territory and suggests that the stock may be overextended.

3. **Technical Indicators**: The stock is currently trading above its 5-Day, 10-Day, and 20-Day moving averages, which could be seen as a bullish signal. However, it is below its 30-Day, 50-Day, and 60-Day moving averages, and the 120-Day, 200-Day, and 250-Day moving averages, which could indicate a bearish outlook in the longer term.

4. **Analyst Ratings**: The consensus rating is a "Strong Buy" with an average price target of $22.17, and the stock has been rated as "Moderate Buy" by analysts with an average 1-year target price of $20.21. This suggests that analysts are optimistic about the stock's future performance.
5. **Recent Developments**: The company has seen significant insider transactions, with the Chief Commercial Officer selling a substantial amount of stock, which could be interpreted as a lack of confidence in the company's short-term prospects.
6. **Market Position**: The company has been experiencing significant growth, but it faces regulatory challenges and the potential impact of FDA decisions. The market is also cautious due to the high P/E ratio and the recent insider selling.

In conclusion, while there are some positive indicators, such as strong revenue growth and a "Strong Buy" consensus rating, the negative trends in profitability, the high and negative P/E ratio, and the recent insider selling suggest that it might not be an opportune time to buy HIMS. Investors should carefully consider these factors and their own investment strategy before making a decision.